Cannabis Health/LinkedIn
Mar 9, 2026, 10:16
Ananda Pharma Cleared to Launch Phase 2 Trial for Endometriosis Pain Treatment – Cannabis Health
Cannabis Health shared a post on LinkedIn:
“Ananda Pharma Ltd has cleared the final regulatory hurdle needed to begin its ENDOCAN Phase 2 clinical trial in women with endometriosis-associated pain.
The company has received approval from the MHRA and NHS Health Research Authority to commence dosing of its proprietary MRX1 CBD oral solution.
Melissa Sturgess, CEO of Ananda Pharma, said: ‘The reason this study is different is that we are using a product that could go all the way through to regulatory approval and be able to be prescribed by a doctor on the NHS.’ ”
Stay updated on all scientific advances in the field of fertility with Fertility News.
-
May 1, 2026, 03:13International Expert Recommendations in Emerging Reproductive Science – ESHRE
-
Apr 30, 2026, 18:45AI in Ultrasound Follicular Monitoring Moves Toward Clinical Decision Support – RBMO
-
Apr 30, 2026, 11:42ASRM Encourages Registration for Conference on Practice Growth and Innovation
-
Apr 30, 2026, 11:26ESHRE and ALPHA Launch Global Survey to Update ART Laboratory KPIs
-
Apr 30, 2026, 11:10Susanne Johnson: Advanced Gynaecology Ultrasound Course Day 2
-
Apr 30, 2026, 11:02Platelets Reduce Oxidative Stress Damage in Human Endometrial Stromal Cells in Vitro – RBMO
-
Apr 30, 2026, 10:57GREEG Day 2026: Elevate Your Ultrasound Expertise – GREEG
-
Apr 30, 2026, 10:49Up to Two-Thirds of Elite Female Athletes Experience Irregular Periods – Fertility Plus
-
Apr 30, 2026, 10:47Applications for the ESHRE5 Young Ambassadors 2026 are Still OPEN, But Not for Long! – ESHRE